Oncologic Benefits of Neoadjuvant Treatment versus Upfront Surgery in Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: Borderline resectable pancreatic cancer (BRPC) has been primarily indicated for neoadjuvant treatment (NAT) in the last decade. This study is the updated meta-analysis for only patients with BRPC including recent NAT regimens such as FOLFIRINOX. The OS, R0 resection rate, and node-ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Jung, Hye-Sol, Kim, Hyeong Seok, Kang, Jae Seung, Kang, Yoon Hyung, Sohn, Hee Ju, Byun, Yoonhyeong, Han, Youngmin, Yun, Won-Gun, Cho, Young Jae, Lee, Mirang, Kwon, Wooil, Jang, Jin-Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497278/
https://www.ncbi.nlm.nih.gov/pubmed/36139520
http://dx.doi.org/10.3390/cancers14184360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497278/
https://www.ncbi.nlm.nih.gov/pubmed/36139520
http://dx.doi.org/10.3390/cancers14184360

Ejemplares similares